Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation

被引:106
作者
Price, Katherine E. [1 ]
Hampton, Thomas H. [1 ]
Gifford, Alex H. [2 ]
Dolben, Emily L. [1 ]
Hogan, Deborah A. [1 ]
Morrison, Hilary G. [3 ]
Sogin, Mitchell L. [3 ]
O'Toole, George A. [1 ]
机构
[1] Geisel Sch Med Dartmouth, Dept Microbiol & Immunol, Hanover, NH 03755 USA
[2] Dartmouth Hitchcock Med Ctr, Sect Pulm & Crit Care Med, Lebanon, NH 03756 USA
[3] Marine Biol Lab, Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Woods Hole, MA 02543 USA
来源
MICROBIOME | 2013年 / 1卷
基金
美国国家卫生研究院;
关键词
Cystic fibrosis; Cystic fibrosis pulmonary exacerbation; Microbiome; Sputum; Pseudomonas aeruginosa; STAPHYLOCOCCUS-AUREUS; PATHOGENESIS; DIVERSITY; DISEASE;
D O I
10.1186/2049-2618-1-27
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Cystic fibrosis (CF) is caused by inherited mutations in the cystic fibrosis transmembrane conductance regulator gene and results in a lung environment that is highly conducive to polymicrobial infection. Over a lifetime, decreasing bacterial diversity and the presence of Pseudomonas aeruginosa in the lung are correlated with worsening lung disease. However, to date, no change in community diversity, overall microbial load or individual microbes has been shown to correlate with the onset of an acute exacerbation in CF patients. We followed 17 adult CF patients throughout the course of clinical exacerbation, treatment and recovery, using deep sequencing and quantitative PCR to characterize spontaneously expectorated sputum samples Results: We identified approximately 170 bacterial genera, 12 of which accounted for over 90% of the total bacterial load across all patient samples. Genera abundant in any single patient sample tended to be detectable in most samples. We found that clinical stages could not be distinguished by absolute Pseudomonas aeruginosa load, absolute total bacterial load or the relative abundance of any individual genus detected, or community diversity. Instead, we found that the microbial structure of each patient's sputum microbiome was distinct and resilient to exacerbation and antibiotic treatment. Conclusion: Consistent with previously reported sputum microbiome studies we found that total and relative abundance of genera at the population level were remarkably stable for individual patients regardless of clinical status. Patient-by-patient analysis of diversity and relative abundance of each individual genus revealed a complex microbial landscape and highlighted the difficulty of identifying a universal microbial signature of exacerbation. Overall, at the genus level, we find no evidence of a microbial signature of clinical stage.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Evidence of an Acinar Response following Treatment for Exacerbation in Adult Patients with Cystic Fibrosis
    Vanderhelst, Eef
    De Meirleir, Liesbeth
    Schuermans, Daniel
    Malfroot, Anne
    Vincken, Walter
    Verbanck, Sylvia
    RESPIRATION, 2014, 87 (06) : 492 - 498
  • [42] Cystic fibrosis clinical score: A new scoring system to evaluate acute pulmonary exacerbation
    Kanga, J
    Kuhn, R
    Craigmyle, L
    Haverstock, D
    Church, D
    CLINICAL THERAPEUTICS, 1999, 21 (08) : 1343 - 1356
  • [43] The Effect of Outpatient Management of Cystic Fibrosis Exacerbation on Pulmonary Function Tests: A Clinical Trial
    Mirlohi, Seyed Hossein
    Daneshibakhtiar, Alireza
    Olfat, Mehrnaz
    Shirzadi, Rohola
    Ghanbari, Niloufar
    Sayedi, Seyed Javad
    Loghmani, Tina
    Modaresi, Mohammad Reza
    INTERNATIONAL JOURNAL OF PEDIATRICS-MASHHAD, 2022, 10 (06): : 16121 - 16126
  • [44] Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis
    Widder, Stefanie
    Carmody, Lisa A.
    Opron, Kristopher
    Kalikin, Linda M.
    Caverly, Lindsay J.
    Lipuma, John J.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [45] Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis
    Somayaji, Ranjani
    Stanojevic, Sanja
    Tullis, D. Elizabeth
    Stephenson, Anne L.
    Ratjen, Felix
    Waters, Valerie
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (09) : 1412 - 1418
  • [46] Clinical characteristics and genotype analysis of patients with cystic fibrosis and nasal polyposis
    Cimmino, M
    Cavaliere, M
    Nardone, M
    Plantulli, A
    Orefice, A
    Esposito, V
    Raia, V
    CLINICAL OTOLARYNGOLOGY, 2003, 28 (02) : 125 - 132
  • [47] Clinical findings of patients with cystic fibrosis according to newborn screening results
    Gursoy, Tugba Ramasli
    Aslan, Ayse Tana
    Asfuroglu, Pelin
    Eyuboglu, Tugba Sismanlar
    Cakir, Erkan
    Cobanoglu, Nazan
    Pekcan, Sevgi
    Cinel, Guzin
    Dogru, Deniz
    Ozcelik, Ugur
    Yalcin, Ebru
    Sen, Velat
    Ercan, Omur
    Kilinc, Ayse Ayzit
    Yazan, Hakan
    Altintas, Derya Ufuk
    Ozturk, Gokcen Kartal
    Bingol, Aysen
    Sapan, Nihat
    Celebioglu, Ebru
    Tugcu, Gokcen Dilsa
    Ozdemir, Ali
    Harmanci, Koray
    Kose, Mehmet
    Emiralioglu, Nagehan
    Tamay, Zeynep
    Yuksel, Hasan
    Ozcan, Gizem
    Topal, Erdem
    Can, Demet
    Ekren, Pervin Korkmaz
    Caltepe, Gonul
    Kilic, Mehmet
    Ozdogan, Sebnem
    PEDIATRICS INTERNATIONAL, 2022, 64 (01)
  • [48] Inhalation Treatment with Glutathione in Patients with Cystic Fibrosis A Randomized Clinical Trial
    Griese, Matthias
    Kappler, Matthias
    Eismann, Claudia
    Ballmann, Manfred
    Junge, Sibylle
    Rietschel, Ernst
    van Koningsbruggen-Rietschel, Silke
    Staab, Doris
    Rolinck-Werninghaus, Claudia
    Mellies, Uwe
    Koehnlein, Thomas
    Wagner, Thomas
    Koenig, Susanne
    Teschler, Helmut
    Heuer, Hans-Eberhard
    Kopp, Matthias
    Heyder, Susanne
    Hammermann, Jutta
    Kuester, Peter
    Honer, Marguerite
    Mansmann, Ulrich
    Beck-Speier, Ingrid
    Hartl, Dominik
    Fuchs, Carola
    Hector, Andreas
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 188 (01) : 83 - 89
  • [49] Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis
    Tunney, M. M.
    Klem, E. R.
    Fodor, A. A.
    Gilpin, D. F.
    Moriarty, T. F.
    McGrath, S. J.
    Muhlebach, M. S.
    Boucher, R. C.
    Cardwell, C.
    Doering, G.
    Elborn, J. S.
    Wolfgang, M. C.
    THORAX, 2011, 66 (07) : 579 - 584
  • [50] An exploratory study of microbial diversity in sinus infections of cystic fibrosis patients by molecular methods
    Rudkjobing, Vibeke Borsholt
    Aanaes, Kasper
    Wolff, Tine Yding
    von Buchwald, Christian
    Johansen, Helle Krogh
    Thomsen, Trine Rolighed
    JOURNAL OF CYSTIC FIBROSIS, 2014, 13 (06) : 645 - 652